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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology with few current
treatment options. Recently, we determined an important role of prostaglandin F2a (PGF2a) in pulmonary fibrosis by using a
bleomycin-induced pulmonary fibrosis model and found an abundance of PGF2a in bronchoalveolar lavage fluid of IPF
patients. We investigated the role of PGF2a in human IPF by assessing plasma concentrations of 15-keto-dihydro PGF2a, a
stable metabolite of PGF2a.
Methods:We measured plasma concentrations of 15-keto-dihydro PGF2a in 91 IPF patients and compared these values with
those of controls (n = 25). We further investigated the relationships of plasma 15-keto-dihydro PGF2a concentrations with
disease severity and mortality.
Results: Plasma concentrations of 15-keto-dihydro PGF2a were significantly higher in IPF patients than controls (p,0.001).
Plasma concentrations of this metabolite were significantly correlated with forced expiratory volume in 1 second (Rs
[correlation coefficient] =20.34, p= 0.004), forced vital capacity (Rs=20.33, p= 0.005), diffusing capacity for carbon
monoxide (Rs=20.36, p= 0.003), the composite physiologic index (Rs= 0.40, p= 0.001), 6-minute walk distance (Rs=20.24,
p= 0.04) and end-exercise oxygen saturation (Rs=20.25, p= 0.04) when patients with emphysema were excluded.
Multivariate analysis using stepwise Cox proportional hazards model showed that a higher composite physiologic index
(relative risk = 1.049, p= 0.002) and plasma 15-keto-dihydro PGF2a concentrations (relative risk = 1.005, p= 0.002) were
independently associated with an increased risk of mortality.
Conclusions: We demonstrated significant associations of plasma concentrations of PGF2a metabolites with disease severity
and prognosis, which support a potential pathogenic role for PGF2a in human IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive,
irreversible and usually lethal lung disease of unknown etiology
that has limited therapeutic options [1]. Although IPF carries an
overall poor prognosis [2], the clinical course of individual patients
varies from slow progression to acute decompensation and death
[3,4]. A variety of pathways and mechanisms underlying
pulmonary fibrosis have been identified [5], but have not been
well evaluated in the clinical arena.
Prostaglandins (PGs) are oxygenated metabolites of arachidonic
acid produced by sequential catalysis of cyclooxygenase (COX)
and respective synthase, and they contribute to a variety of
physiological responses and pathological processes [6]. PGE2 and
PGI2 are considered to exert antifibrotic effects [7]. However, we
recently reported that PGF2a facilitates pulmonary fibrosis
through PGF receptor (FP) in a murine bleomycin-induced
pulmonary fibrosis model [8]. In addition, PGF2a is abundant in
bronchoalveolar lavage fluid of human subjects with IPF, and
stimulates proliferation and collagen production of lung fibroblasts
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via FP [8]. This indicates that PGF2a produced in the lung of IPF
patients may contribute to disease progression.
Endogenous PGF2a is swiftly degraded in various organs
including the lung to 13,14-dihydro-15-keto PGF2a (15-keto-
dihydro PGF2a), a stable metabolite of PGF2a, which has a longer
half-life in the circulation and has been used as a reliable indicator
of in vivo PGF2a biosynthesis [9]. In the current study, we
measured plasma concentrations of this metabolite in a cohort of
IPF patients to clarify their clinical relevance and prognostic value.
Methods
Ethics Statement
This study was approved by Kyoto University Graduate School
and Faculty of Medicine Ethics Committee and the Ethics
Committee of Tenri Hospital, and written informed consent was
obtained from all patients.
Study Subjects
The study population consisted of 91 IPF patients who visited
Kyoto University Hospital from February 2008 through August
2011, and those who visited Tenri Hospital from April 2006
through September 2008. At the time of study entry, all of study
patients had not been receiving any specific treatment for IPF.
IPF was diagnosed on the basis of the current official joint
statement on IPF [10]. In 28 patients, usual interstitial pneumonia
was confirmed by surgical lung biopsy. Quantification of disease
severity by pulmonary function tests [11], and suitability of
prognostic indicators [12] may be confounded by coexistent
emphysema in patients with IPF. Therefore we also performed a
subgroup analysis of patients without emphysema. Emphysema on
high-resolution computed tomography was defined as the presence
of well-demarcated areas of decreased attenuation in comparison
with contiguous normal lung, and delimited by a very thin
(,1 mm) or no wall, with upper zone predominance [13]. Age-
and body mass index-matched subjects without lung disease
(n = 25) were recruited as controls.
Physiological Assessments
Pulmonary function tests were performed using CHESTAC
system (Chest M.I. Inc., Tokyo, Japan). Diffusing capacity for
carbon monoxide (DLCO) was measured using the single-breath
technique. Percent-predicted values were used for analyses. The
composite physiologic index (CPI) was calculated as previously
described [11]. Arterial blood gas analysis, including arterial
partial pressure of oxygen (PaO2) and arterial partial pressure of
carbon dioxide (PaCO2), was performed while patients were
breathing room air at rest in the supine position. The alveolar-
arterial oxygen pressure difference (A-aDO2) was calculated
according to a standard formula, using the respiratory exchange
ratio of 0.8. Six-minute walk testing (6MWT) was performed as
recommended by American Thoracic Society guidelines [14] and
oxygen saturation was continuously monitored during 6MWT
using a pulse oximeter (Pulsox-300i, Konica Minolta Inc., Osaka,
Japan).
Blood Sample Collection and Laboratory Assessments
Samples of peripheral venous blood were collected in the
morning before breakfast. Plasma concentrations of 15-keto-
dihydro PGF2a were measured using an enzyme immunoassay kit
(13,14-dihydro-15-keto Prostaglandin F2a EIA kit; Cayman
Chemical; Ann Arbor, MI, USA). Serum KL-6 levels were
measured by a sandwich-type electrochemiluminescence immu-
noassay kit (Picolumi KL-6; Sanko Junyaku, Tokyo, Japan) and
serum SP-D levels were measured by a sandwich-type enzyme
immunoassay kit (SP-D kit Yamasa EIA II; Yamasa Shoyu, Chiba,
Japan).
Doppler Echocardiography
Twenty-eight IPF patients recruited in Kyoto University
Hospital underwent Doppler echocardiography at study entry.
Doppler echocardiography was performed using conventional
clinical echocardiographic equipment (Xario XG, Toshiba Med-
ical Systems Co., Ltd, Tochigi, Japan). Systolic pulmonary arterial
pressure (sPAP) at rest was calculated by the sum of estimated right
atrial pressure and the transtricuspid gradient as previously
reported [15]. Pulmonary hypertension (PH) was defined as sPAP
of greater than or equal to 40 mmHg at rest [15].
Statistics
All statistical analyses were performed using JMP version 9 (SAS
Institute, Cary, NC, USA). Continuous variables are expressed as
mean6standard deviation. Comparisons of categorical data
between two groups were performed by Fisher’s exact probability
tests. Continuous variables were compared with the unpaired t-test
if normally distributed, and the Mann-Whitney U test when the
distribution was not normal. Correlations between pairs of
variables were analyzed by Spearman’s rank correlation tests.
For survival analysis, patients receiving lung transplantation
during follow-up (n = 1) or subjects lost to follow-up (n= 10) were
censored, and then the duration from entry to death, the
transplant date, or the last visit was recorded. Mortality was first
assessed for all risk factors using univariate Cox proportional
hazard analysis, and then stepwise multivariate Cox proportional
hazard analysis was performed to examine the prognostic
predictive value of plasma 15-keto-dihydro PGF2a concentrations
while adjusting for other clinical predictors of cumulative
mortality. Results of the regression analysis were presented in
terms of relative risks (RRs) with corresponding 95% confidence
intervals. Survival curves were obtained using the Kaplan-Meier
method and the difference in survival rates between subgroups was
calculated using a log-rank test. A p value less than 0.05 was
considered to indicate statistical significance.
Results
Plasma 15-keto-dihydro PGF2a Concentrations Correlate
with Disease Severity Indices
The clinical characteristics of patients and controls are
summarised in Table 1 (see Table S1 for the patient characteristics
in each hospital). The proportions of females (p=0.03) and never
smokers (p,0.001) were significantly lower in IPF patients than
those in control subjects. Among all 91 patients, 16 had concurrent
emphysema. Plasma concentrations of 15-keto-dihydro PGF2a
were significantly higher in IPF patients than those in control
subjects, regardless of the presence of concurrent emphysema
(Figure 1, p,0.001).
To assess the clinical relevance of plasma 15-keto-dihydro
PGF2a concentrations, we investigated their relationships with
disease duration, pulmonary function, arterial blood gas data and
6MWT data (Table 2). Spearman’s rank correlation analysis
showed that plasma concentrations of 15-keto-dihydro PGF2a
were significantly correlated with forced expiratory volume in 1
second (FEV1) (Rs [correlation coefficient] =20.22, p=0.03) but
not with disease duration or other indices of disease severity.
However, among patients without emphysema (n= 75), plasma
concentrations of 15-keto-dihydro PGF2a were significantly
correlated with FEV1 (Rs=20.34, p=0.004), forced vital capacity
Plasma PGF2a Metabolite in IPF
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(FVC) (Rs=20.33, p=0.005), DLCO (Rs=20.36, p=0.003), CPI
(Rs=20.40, p=0.001), A-aDO2 (Rs=0.39, p=0.002), 6-minute
walk distance (Rs=20.24, p=0.04) and end-exercise oxygen
saturation (Rs=20.25, p=0.04) (Figure 2).
Plasma 15-keto-dihydro PGF2a Concentrations Predict
Mortality
During a mean follow-up period of 29.8 (range: 0.5–74.9)
months, 22 of 91 patients died. The major cause of death was
respiratory failure due to the progression of IPF (n= 15), 4 patients
died of lung cancer and 3 patients died suddenly at home from an
unknown cause. Although none of the patients received IPF-
specific treatment at entry, some underwent treatment with
pirfenidone (n= 13), prednisone (n= 25), cyclophosphamide
(n= 3), azathioprine (n = 4) and cyclosporine (n = 6) during a
follow-up period. Combination therapy with two or more
medications was used in 14 patients.
We assessed the relationships between clinical measurements
and mortality using Cox proportional hazard model (Table 3).
Among overall patients (n = 91) as well as patients without
emphysema (n= 75), low FEV1, low FVC, low DLCO, high CPI,
short 6-minute walk distance and low end-exercise oxygen
saturation were significantly associated with an increased risk of
mortality. Plasma concentrations of 15-keto-dihydro PGF2a were
significantly associated with mortality (RR=1.005, p,0.001), but
sex, age and serum levels of KL-6 and SP-D were not.
Multivariate analysis was performed using stepwise Cox propor-
tional hazard model in which all significant predictors of mortality
in univariate analyses were included as covariates. We found that
high CPI (RR=1.049, p=0.002 in all patients; RR=1.043,
p=0.016 in patients without emphysema) and increased plasma
concentrations of 15-keto-dihydro PGF2a (RR=1.005, p=0.002
Figure 1. Comparison of plasma 15-keto-dihydro prostaglan-
din F2a concentrations in patients and controls. Horizontal bars
indicate mean values. There were significant differences in plasma 15-
keto-dihydro prostaglandin F2a concentrations between IPF patients
with emphysema (n = 16) and controls (n = 25), and IPF patients without
emphysema (n = 75) and controls. However, there was no difference in
plasma 15-keto-dihydro prostaglandin F2a concentrations between IPF
patients with emphysema and those without emphysema.
doi:10.1371/journal.pone.0066017.g001
Table 1. Characteristics of patients and controls.
All patients (n=91)
Emphysema
excluded (n=75) Controls (n=25) p value*
Sex, male/female 69/22 57/18 13/12 0.03
Age, years 66.567.9 66.067.8 64.666.4 0.27
BMI, kg/m2 23.463.0 23.463.0 23.262.2 0.80
Nonsmokers 15 14 16 ,0.001
Disease duration**, months 16.0625.5 16.3625.4 NA
FEV1, % predicted 98.6621.0 98.5621.6 NA
FVC, % predicted 89.2622.1 87.6620.9 NA
DLCO, % predicted 52.6617.7 52.1616.5 NA
Composite physiologic index 43.8614.0 43.7613.9 NA
PaCO2, kPa 5.760.9 5.760.8 NA
PaO2, kPa 10.961.7 11.361.6 NA
A-aDO2, kPa 1.461.9 1.261.7 NA
Six-minute walk distance, m 449.1692.0 454.9687.2 NA
End-exercise oxygen saturation, % 87.966.9 88.766.4 NA
Serum KL-6, U/mL 11356842 11126829 NA
Serum SP-D, ng/mL 2536211 2636199 NA
Plasma15-keto-dihydro PGF2a, pg/mL 1936133 1946140 37619 ,0.001
Data are presented as mean6standard deviation.
*Comparison between all patients and controls.
**Time from diagnosis to blood sample collection.
BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; PaCO2, arterial partial
pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; A-aDO2, alveolar-arterial oxygen pressure difference; SP-D, surfactant protein-D; PGF2a,
prostaglandin F2a; NA, not available.
doi:10.1371/journal.pone.0066017.t001
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Figure 2. Correlations of plasma 15-keto-dihydro prostaglandin F2a concentrations with indices of disease severity. Scatter diagrams
show the correlations of plasma 15-keto-dihydro prostaglandin F2a concentrations with FVC (a), DLCO (b), six-minute walk distance (c) and end-
exercise oxygen saturation (d) in IPF patients without emphysema. The Rs value indicates the correlation coefficient.
doi:10.1371/journal.pone.0066017.g002
Table 2. Relationships between plasma 15-keto-dihydro prostaglandin F2a concentrations and clinical parameters in patients with
idiopathic pulmonary fibrosis.





Disease duration*, months 20.04 0.20 0.03 0.80
Pulmonary function
FEV1, % predicted 20.22 0.03 20.34 0.004
FVC, % predicted 20.11 0.28 20.33 0.005
DLCO, % predicted 20.16 0.13 20.36 0.003
Composite physiologic index 0.19 0.08 0.40 0.001
Arterial blood gas data
PaCO2, kPa 20.09 0.40 20.13 0.30
PaO2, kPa 20.14 0.22 20.24 0.05
A-aDO2, kPa 0.21 0.06 0.39 0.002
Six-minute walk test
Six-minute walk distance, m 20.21 0.06 20.24 0.04
End-exercise oxygen saturation, % 20.14 0.20 20.25 0.04
*Time from diagnosis to blood sample collection.
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; PaCO2, arterial partial pressure of carbon dioxide;
PaO2, arterial partial pressure of oxygen; A-aDO2, alveolar-arterial oxygen pressure difference.
doi:10.1371/journal.pone.0066017.t002
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in all patients; RR=1.005, p=0.003 in patients without emphy-
sema) were the independent predictors of mortality. The
independent association of plasma 15-keto-dihydro PGF2a con-
centrations with mortality was reproducibly found in each cohort
(see Table S2).
Figure S1 shows the Kaplan-Meier survival curves when
patients were divided into two groups, with plasma 15-keto-
dihydro PGF2a concentrations above or below the median value
(156 pg/mL), respectively. Patients with higher plasma 15-keto-
dihydro PGF2a concentrations ($156 pg/mL) had a significantly
worse prognosis than patients with lower concentrations (p=0.04).
Plasma 15-keto-dihydro PGF2a Concentrations are
Associated with the Presence of Pulmonary Hypertension
Assessed by Doppler Echocardiography
Finally, since PH is a significant comorbidity which can affect
prognosis in patients with IPF [16,17], we compared plasma 15-
keto-dihydro PGF2a concentrations according to the presence or
absence of PH. Among patients with successful sPAP measure-
ments, 8 of 28 had sPAP$40 mmHg, which fulfilled the definition
of PH. Plasma concentrations of 15-keto-dihydro PGF2a were
significantly higher in patients with PH than in those without PH
(3176291 pg/mL vs 172675 pg/mL, p=0.04). However, there
were no significant differences in serum levels of KL-6 and SP-D
between patients with and without PH (15036444 U/mL vs
12526735 U/mL, p=0.38; and 3676181 ng/mL vs
3476314 ng/mL, p=0.87, respectively).
Discussion
We demonstrated raised concentrations of 15-keto-dihydro
PGF2a, a stable metabolite of PGF2a, in the plasma of patients
with IPF. Plasma concentrations of this metabolite were signifi-
cantly correlated with indices of disease severity including FEV1,
FVC, DLCO, CPI, 6-minute walk distance and end-exercise
oxygen saturation, when patients with emphysema were excluded.
Furthermore, in our cohort of patients, higher plasma 15-keto-
dihydro PGF2a concentrations were significantly associated with
an increased risk of mortality after adjusting for disease severity
indices represented by CPI. Among patients with successful
echocardiographic measurements, plasma 15-keto-dihydro PGF2a
concentrations were significantly higher in patients with PH than
in those without PH.
Considering that IPF is a devastating lung disease with poor
prognosis but highly variable clinical course, predicting which
paths individual patients will take remains a central challenge for
clinicians [18]. A primary finding of the present study was that
plasma concentrations of PGF2a metabolite were significantly
correlated with the severity of IPF as well as mortality. However,
the relationships of plasma 15-keto-dihydro PGF2a concentrations
with pulmonary function, arterial blood gas data and 6MWT data
differed according to the presence of concomitant emphysema,
suggesting that emphysema is a significant confounding comor-
bidity in IPF. FVC, DLCO, CPI and desaturation during 6MWT
predicted mortality in our cohort of patients with IPF, which is
consistent with previous studies [11,17,19,20]. However, even
after adjusting for these physiologic predictors, plasma 15-keto-
dihydro PGF2a concentrations were significantly associated with
mortality. We have recently shown by both in vivo and in vitro
approaches that PGF2a-FP signaling mediates pulmonary fibrosis
independently of transforming growth factor-b signaling [8],
which is a well-known crucial pathway for fibrogenesis [21].
Raised concentrations of plasma PGF2a metabolite may reflect an
upregulation of PGF2a-FP signaling pathway and subsequent
fibrotic processes, which cannot be evaluated by a single
measurement of pulmonary function or 6MWT. Indeed, the
relationships between plasma concentration of PGF2a metabolite
and physiological parameters of IPF tended to be significant but
relatively weak.
Table 3. Cox proportional hazard model results for evaluating the risk of mortality.
All patients (n=91) Emphysema excluded (n=75)
Relative risk 95% CI p value Relative risk 95% CI p value
Univariate analysis
Female sex 0.386 0.090–1.667 0.20 0.372 0.086–1.613 0.19
Age, years 1.028 0.964–1.095 0.40 1.036 0.965–1.112 0.32
Smoking, pack-years 0.997 0.984–1.010 0.61 1.000 0.988–1.012 0.94
FEV1, % predicted 0.972 0.949–0.996 0.02 0.974 0.950–0.998 0.03
FVC, % predicted 0.963 0.941–0.986 0.002 0.961 0.938–0.985 0.002
DLCO, % predicted 0.952 0.922–0.983 0.003 0.956 0.927–0.986 0.005
Composite physiologic index 1.060 1.022–1.099 0.002 1.059 1.021–1.099 0.002
Six-minute walk distance, m 0.994 0.990–0.999 0.02 0.991 0.986–0.997 0.002
End-exercise oxygen saturation, % 0.908 0.852–0.969 0.004 0.878 0.819–0.943 ,0.001
Serum KL-6, U/mL 1.000 1.000–1.001 0.52 1.000 1.000–1.001 0.63
Serum SP-D, ng/mL 1.001 0.999–1.003 0.46 1.002 0.999–1.004 0.22
Plasma 15-keto-dihydro PGF2a, pg/mL 1.005 1.002–1.007 ,0.001 1.005 1.002–1.007 ,0.001
Multivariate analysis
Composite physiologic index 1.049 1.016–1.088 0.002 1.043 1.008–1.084 0.016
Plasma 15-keto-dihydro PGF2a, pg/mL 1.005 1.002–1.007 0.002 1.005 1.002–1.008 0.003
CI, confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; SP-D, surfactant protein-D;
PGF2a, prostaglandin F2a.
doi:10.1371/journal.pone.0066017.t003
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Another possible explanation why plasma PGF2a metabolite
concentrations predicted mortality was the impact of comorbid
PH. In subgroup analysis, plasma PGF2a metabolite concentra-
tions were significantly higher in patients with PH, whereas serum
levels of KL-6 and SP-D did not differ between the subgroups.
Since PH commonly complicates the course of IPF and potentially
affects prognosis [16,17], the significant relationship of plasma
PGF2a metabolite concentrations with mortality may also reflect a
higher frequency of concomitant PH in patients with higher
plasma concentrations of PGF2a metabolite.
Since PGF2a is a locally bioactive hormone that is uncovered
virtually in all tissues including lung [9], the source of PGF2a or its
metabolite in the plasma of pulmonary fibrosis patients is
speculative. For example, macrophages activated by proinflam-
matory stimuli produce PGF2a in large amounts [22]. PGF2a is
also produced by type II alveolar epithelial cells [23], and widely
upregulated COX-2 expression was observed in metaplastic
epithelium in pulmonary fibrous disorders [24]. In addition,
PGF synthase exists in contractile interstitial cells of bovine lungs,
which are considered to be a precursor of myofibroblasts, main
contributing cell types to fibrogenesis [25]. Thus, increased
epithelial permeability in the lung of IPF patients [26] may allow
PGF2a produced in the lungs to leak into the circulation, where it
is instantly bioconverted through metabolism [9].
Another possible mechanism might be functional alteration in
pulmonary arterial endothelium and/or smooth muscle cells, both
of which play significant roles in the pathogenesis of pulmonary
arterial hypertension [27]. Recent studies suggested that the
pathogenesis of PH in IPF is a complicated interaction of epithelial
cells, fibroblasts and vascular cells mediated by multiple factors
including several growth factors [28], which can stimulate the
expression of COX-2, thereby leading to the production of PGs
[29]. The COX-2 pathway might be upregulated in pulmonary
arterial endothelium and/or smooth muscle cells through hypoxic
stimulus and/or the development of PH. This pathogenesis is
worthy to be studied further because, in contrast, previously
identified biomarkers of IPF, KL-6 and SP-D, were found to be
mainly produced by alveolar epithelial cells [30,31].
Cytosolic phospholipase A2 (cPLA2), which cleaves phospholip-
ids and yields arachidonic acids including PGs as well as
lysophospholipids, might play a pivotal role in the pathogenesis
of pulmonary fibrosis [32]. Thus, PGF2a and lysophosphatidic
acids, both derived from the breakdown of phospholipids by
cPLA2 and possible stimulators of fibrosis [8,33], might act
complementarily to affect the progression of disease.
The present study has some limitations. Firstly, this is a
relatively small cohort study with IPF patients alone. Since PGF2a
is produced by various cells and is implicated in the regulation of
intricate pathophysiological processes [9], further studies on the
utility of plasma 15-keto-dihydro PGF2a in patients with systemic
disease-associated interstitial lung diseases are warranted. At the
time of blood sampling, all study participants were not receiving
any specific treatment for IPF. Hence the possible effects of IPF-
specific medication on the value and usefulness of plasma 15-keto-
dihydro PGF2a should also be assessed for future clinical use.
Secondly, since the presence and degree of PH were not evaluated
by right heart catheterisation and echocardiographic data were
not available in all patients, our current findings should be
interpreted with caution and further studies are necessary.
In summary, we demonstrated significant associations of plasma
concentrations of PGF2a metabolites with disease severity and
prognosis in IPF patients. Although further larger studies are
needed to confirm the clinical utility of this metabolite, the current
findings support a potential pathogenic role for PGF2a in human
IPF. Our current results also provide a more integrated
understanding of this devastating and complex disease and may
help in the development of new antifibrotic drugs.
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